• ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT

INVESTORS

[서울경제] “CAR-T임상 유럽학회 발표…기업가치 높여 IPO 재도전”

2022/05/03

‘CAR-T임상 유럽학회 발표…기업가치 높여 IPO 재도전’ | 서울경제 (sedaily.com)

서울경제 안경진 기자

Prev[이데일리] [큐로셀 대해부]③“상장되면?…2차 치료제용 CAR-T 임상도 도전”[이데일리]
Next큐로셀, 세계적 권위의 유럽혈액학회(EHA)에서 국내 최초 CAR-T 치료제 ‘안발셀(Anbal-cel)’ 임상 1상 구두발표
Copyright 2023. Curocell Inc. All Rights Reserved.
Created by PRESSCAT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
  • ABOUT US
  • SCIENCE
  • FACILITY
  • INVESTORS
    • Media
    • Notice
    • Public Disclosures
    • Stock Information
    • Financials
  • ESG
    • ESG Management
    • Archive
  • CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.